Adaptive A. I. Validates C. V. Event Adjudication 04/01/26
Welcome to Cardiology Today â Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.
Article Links:
Article 1: Angiography-Based Physiology to Guide Coronary Revascularization. (The New England journal of medicine)
Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. (The New England journal of medicine)
Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial. (Journal of the American College of Cardiology)
Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis. (Circulation)
Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/
đ Featured Articles
Article 1: Angiography-Based Physiology to Guide Coronary Revascularization.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910382
Summary: This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.
Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910380
Summary: This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.
Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41914946
Summary: V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.
Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41914183
Summary: R. – ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. – C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. – proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. – proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. – C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.
Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41911340
Summary: I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. – C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. – C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost.
đ Transcript
Today’s date is April 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Angiography-Based Physiology to Guide Coronary Revascularization. This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.
Article number two. Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.
Article number three. I. V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.
Article number four. M. R. – ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. – C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. – proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. – proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. – C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.
Article number five. Adaptive A. I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. – C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. – C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
high-risk P. C. I., mid-regional pro-adrenomedullin, intermediate coronary lesions, prognosis stratification, severe left ventricular dysfunction, stroke, percutaneous coronary intervention, cardiovascular events, microaxial flow pump, N-terminal pro-B-type natriuretic peptide, biomarkers, transthyretin amyloid cardiomyopathy, double kissing crush, intravascular ultrasound, angiography guidance, artificial intelligence, myocardial infarction, clinical endpoint adjudication, coronary revascularization, coronary bifurcation lesions, pressure-wire fractional flow reserve, left ventricular unloading, angiography-derived fractional flow reserve.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow